KUALA LUMPUR, Crown Bioscience, a global contract research organisation (CRO) has announced an expansion of its facility in Singapore with new oncology research models and state-of-the-art imaging technologies. Located in the epicentre of Asia's biomedical sciences hub, the enhanced facility is set to bolster the company's support for both global and local biotech and pharmaceutical companies engaged in preclinical and translational oncology drug discovery and development. 'The expansion of our Singapore facility not only amplifies our oncology research capabilities but also reflects our strategic initiative to diversify our global operational bases and enhance accessibility in key regions. 'This ensures that we can continue to provide our clients with unmatched precision and efficiency in preclinical and translational drug research and development,' said Crown Bioscience Interim Chief Executive Officer, John Gu in a statement. Opened in 2023, the Singapore facility enhances Crown Bioscience's strategic global presence, which spans 12 locations worldwide, and offers an extensive selection of oncology models, utilising in vivo syngeneic, cell-derived xenograft (CDX), and patient-derived xenograft (PDX) models. Tapping into its prime location and strong partnerships with leading science and technology providers, the facility is now equipped with advanced Magnetic Resonance Imaging (MRI) for orthotopic and systemic models, In Vivo Imaging Systems (IVIS), and its transient human immunity platform (MiXeno), alongside comprehensive biomarker services. Headquartered in California, United States, Crown Bioscience is a part of JSR Life Sciences and JSR Corporation, dedicated to improving human health via partnering with biotech and pharmaceutical companies that drive the discovery and development of oncology drugs. Source: BERNAMA News Agency